Last10K.com

Ideaya Biosciences, Inc. (IDYA) SEC Filing 10-K Annual report for the fiscal year ending Thursday, December 31, 2020

Ideaya Biosciences, Inc.

HISTORY TOOLS
CIK: 1676725 Ticker: IDYA

Exhibit 99.1

 

IDEAYA Biosciences, Inc. Reports Fourth Quarter 2020

Financial Results and Provides Business Update

 

 

-

Initiated Phase 1 clinical trial for IDE397, a potential best-in-class MAT2A inhibitor for patients having tumors with MTAP-deletion

 

-

Planning to present data at AACR in April 2021 for IDE397 (monotherapy efficacy in over forty PDX models with homozygous MTAP deletions across tumor types) and for PARG (monotherapy efficacy in CDX and PDX models based on defined biomarker)

 

-

Hosting inaugural IDEAYA Synthetic Lethality Investor Day April 20, 2021 at 1:00 pm ET

 

-

Targeting Development Candidates for PARG and Pol Theta programs in 2021

 

-

Initiated dose expansion in the Phase 1/2 study of IDE196 / binimetinib combination in metastatic uveal melanoma (MUM) based on early clinical activity

 

-

Targeting interim data for IDE196 / binimetinib combination in MUM and for IDE196 monotherapy in MUM and GNAQ/11-mutation skin melanoma in 2021, including tolerability, clinical efficacy, and survival data for IDE196 monotherapy

 

South San Francisco, CA, March 23, 2021 – IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the fourth quarter ended December 31, 2020.

“In the last quarter, we have made important progress towards our goal to build a preeminent synthetic lethality-focused precision medicine oncology company, including advancing IDE397 into Phase 1 as a potential best-in-class MAT2A inhibitor to treat patients with MTAP-deletion, which represents approximately 15% of all solid tumors. We are also poised to expand our synthetic lethality pipeline, targeting Development Candidate nominations in 2021 for each of our potential first-in-class PARG and Pol Theta programs.  Lastly, IDE196 has reached a key inflection point as we initiated dose expansion in our Phase 1/2 study evaluating the IDE196 / binimetinib combination in the GNAQ/11 mutation-driven cancer of metastatic uveal melanoma,” said Yujiro S. Hata, Chief Executive Officer and President of IDEAYA Biosciences.

 


The following information was filed by Ideaya Biosciences, Inc. (IDYA) on Tuesday, March 23, 2021 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Ideaya Biosciences, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Ideaya Biosciences, Inc..

Continue

Assess how Ideaya Biosciences, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Ideaya Biosciences, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Revenue
Financial
Other
Filter Subcategory:
All
Product
Expense
Income
Debt
Shares
Other
Inside Ideaya Biosciences, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Balance Sheets
Balance Sheets (Parenthetical)
Statements Of Cash Flows
Statements Of Operations And Comprehensive Loss
Statements Of Redeemable Convertible Preferred Stock And Stockholders' Equity (Deficit)
Statements Of Redeemable Convertible Preferred Stock And Stockholders' Equity (Deficit) (Parenthetical)
401(K) Retirement Savings Plan
401(K) Retirement Savings Plan - Additional Information (Details)
Balance Sheet Components
Balance Sheet Components (Tables)
Balance Sheet Components - Additional Information (Details)
Balance Sheet Components - Summary Of Accrued Liabilities (Details)
Balance Sheet Components - Summary Of Property And Equipment, Net (Details)
Commitments And Contingencies
Common Stock
Common Stock (Tables)
Common Stock - Additional Information (Details)
Common Stock - Schedule Of Number Of Common Stock Reserved For Future Issuance (Details)
Fair Value Measurement And Marketable Securities
Fair Value Measurement And Marketable Securities (Tables)
Fair Value Measurement And Marketable Securities - Additional Information (Details)
Fair Value Measurement And Marketable Securities - Schedule Of Financial Assets Measured And Recognized At Fair Value (Details)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Details)
Income Taxes - Schedule Of Provision For Income Taxes (Details)
Income Taxes - Schedule Of Tax Effects Of Temporary Differences And Carryforwards Of Deferred Tax Assets (Details)
Income Taxes - Summary Of Activity Related To Company's Unrecognized Tax Benefits (Details)
Net Loss Per Share Attributable To Common Stockholders
Net Loss Per Share Attributable To Common Stockholders (Tables)
Net Loss Per Share Attributable To Common Stockholders - Additional Information (Details)
Net Loss Per Share Attributable To Common Stockholders - Computation Of Basic And Diluted Net Loss Per Share Attributable To Common Stockholders (Details)
Net Loss Per Share Attributable To Common Stockholders - Schedule Of Outstanding Shares Of Potentially Dilutive Securities Excluded From The Computation Of Diluted Net Loss Per Share (Details)
Operating Leases
Operating Leases (Tables)
Operating Leases - Additional Information (Details)
Operating Leases - Schedule Of Maturities Of Operating Lease Liabilities (Details)
Organization
Organization - Additional Information (Details)
Related Party Transactions
Related Party Transactions - Additional Information (Details)
Revenue Recognition
Revenue Recognition (Tables)
Revenue Recognition - Contract Balances - Additional Information (Details)
Revenue Recognition - Performance Obligations - Additional Information (Details)
Revenue Recognition - Summary Of Changes In Contact Liabilities (Details)
Revenue Recognition - Summary Of Revenue Disaggregated By Research Program (Details)
Revenue Recognition - Summary Of Transaction Price Allocated To Remaining Performance Obligations (Details)
Significant Agreements
Significant Agreements - Additional Information (Details)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Additional Information (Details)
Stock-Based Compensation - Assumptions Used To Calculate Fair Values Of Options (Details)
Stock-Based Compensation - Summary Of Activity Under Plans (Details)
Stock-Based Compensation - Summary Of Restricted Stock Activity (Details)
Stock-Based Compensation - Summary Of Stock-Based Compensation Expense (Details)
Subsequent Event
Subsequent Event - Additional Information (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies - Additional Information (Details)
Ticker: IDYA
CIK: 1676725
Form Type: 10-K Annual Report
Accession Number: 0001564590-21-014676
Submitted to the SEC: Tue Mar 23 2021 6:30:49 AM EST
Accepted by the SEC: Tue Mar 23 2021
Period: Thursday, December 31, 2020
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/idya/0001564590-21-014676.htm